Research summary

Egrifta is prescription tesamorelin approved in the United States for a narrow indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss.[1]

Remy Research tesamorelin is supplied for in-vitro laboratory research only, not for human or veterinary use.

Summary revised November 1, 2026. This editorial update does not constitute a new literature review.

Update History ▾
October 24, 2026: Added an AI-generated image of the ProPeptide Tesamorelin 20mg Pen (the model is not a customer).
October 23, 2026: Purity wording follows the 99%+ line standard.
October 21, 2026: The Tesamorelin 10mg vial now has a published METS Lab batch report (TSM10V-001: 99.31% HPLC purity, 9.98 mg content, report issued 19 October 2026); the intro, documentation table, testing FAQ and supplier-check note name it.
October 19, 2026: The Genovare pens on this page now read the 99%+ line standard (owner order, 19 October).
October 17, 2026: The price table now gives AED per labelled mg to two decimals, from the same formula as the catalogue.
October 12, 2026: Added the 2026 placebo-controlled cognition pilot (PMID 42382101) and the recruiting non-HIV peripheral nerve-injury trial (NCT03150511); corrected the ClinicalTrials.gov count to 23 studies by excluding one record labelled a mock study, and replaced the raw API link with the registry search page; replaced the statement that published batch reports cover only the Retatrutide range with a pointer to the lab results library; re-checked the listing table against the catalogue; fixed two escaped links in the structured citations.
October 7, 2026: Initial publication, built from the July 2026 Egrifta label, Drugs@FDA, EMA, Health Canada and WADA records, and a source-by-source check of the tesamorelin trial literature. Corrected the same day: the 2025 HIV cognition trial is no longer listed among the studies outside HIV.
Research-use-only framing applied throughout in line with Remy editorial standards.
Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

Tesamorelin prices in Dubai and the UAE (AED)

Remy Research lists 3 Tesamorelin products, 2 in stock, from AED 355 per unit. Prices and stock as of . Multi-unit prices are per unit. Dubai orders placed before 4 PM are delivered the same day; delivery costs AED 50 below AED 1,000 and is free from AED 1,000. A batch report names the batch the lab tested; some are supplier-mapped to other strengths (each product page says which), and a report does not confirm the current shipping lot. Research use only.

ProductFormat1 unit2+ each5+ eachLowest AED/mgStockPublished batch report
Genovare Tesamorelin 25mg AQ PenPenAED 1,000——AED 40.00In stock—
ProPeptide Tesamorelin 10mg VialVialAED 355AED 330AED 300AED 30.00Out of stockMETS Lab, batch TSM10V-001
ProPeptide Tesamorelin 20mg PenPenAED 700——AED 35.00Out of stock—

Evidence and context

Two different things are sold as "tesamorelin". One is Egrifta, a US prescription medicine approved for a single, narrow use. The other is research-use-only tesamorelin from peptide suppliers, which is not Egrifta. Egrifta is FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it is not for weight loss.[1][2] It was never authorised in the EU, its Canadian listings are cancelled, and we found no UAE registration.[3][4]

For researchers in Dubai, that means the useful questions are about identity and documentation: what the vial contains, how much of the stated mass is peptide, and whether a batch report backs the purity figure. Remy Research lists the Tesamorelin 10mg vial at AED 355 (AED 300 at the 5+ tier) to a ≥99% HPLC line standard, and its METS Lab batch report (TSM10V-001) records 99.31% HPLC purity. Material is supplied for in-vitro laboratory research only — not for human or veterinary use.

Egrifta and Research Tesamorelin Are Not the Same Product

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). The approved form is made by Theratechnologies and sold in the US as Egrifta: first approved in November 2010, followed by the Egrifta SV formulation in November 2018 and Egrifta WR in March 2025.[2][5][6] All three carry one indication: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy". The label adds that it is not indicated for weight-loss management because it has a weight-neutral effect, and that long-term cardiovascular safety has not been established.[1]

Research tesamorelin sold by peptide suppliers in the UAE is not made by Theratechnologies, is not covered by the Egrifta label's quality and safety data, and is not an approved medicine anywhere. Some social-media posts describe tesamorelin as "FDA-approved for fat loss"; that is not what the approval says. A search for "Egrifta Dubai" returns the US label and manufacturer pages, not a UAE pharmacy or registry entry.

Identity and Mass Labelling

Tesamorelin is the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoyl group added to the N-terminal tyrosine. PubChem lists the free base as C221H366N72O67S, CAS number 218949-48-5, PubChem CID 16137828; the FDA label gives a molecular weight of 5135.9 Da.[7][1] In vitro it binds and stimulates the human GHRH receptor with potency similar to the native hormone, and the label reports a mean elimination half-life of about 8 minutes in healthy subjects.[1]

The approved drug is an acetate salt, and the label itself distinguishes tesamorelin mass from tesamorelin-acetate mass.[1] That matters when comparing listings: a "10mg" research vial can mean 10mg of peptide or 10mg of salt, and a certificate should say which. For how tesamorelin compares with CJC-1295, sermorelin and ipamorelin, see the GHRH peptides comparison.

What the Evidence Covers — and Who It Covers

Almost all human tesamorelin data come from adults with HIV. The full trial-by-trial review is in the Tesamorelin research review; the summary below is what a sourcing decision needs.

Area What was reported Population
Visceral fat Two phase 3 trials (806 patients pooled) cut visceral fat by about 15% against placebo over 26 weeks, with subcutaneous fat unchanged HIV lipodystrophy
After stopping Visceral fat returned once treatment ended in the extension phases HIV lipodystrophy
Liver fat A 12-month NIH-funded trial reduced hepatic fat fraction (relative fall of about 37%) HIV with NAFLD
Meta-analysis 2026 Five RCTs: less visceral and liver fat, slightly more lean mass, no change in BMI HIV lipodystrophy
Type 2 diabetes A 12-week safety trial found no change in glycaemic control Non-HIV, 53 adults
Cognition One positive trial in older adults (2012); a 2025 HIV trial and a 2026 pilot in older adults found no significant cognitive change Mixed, small

The first phase 3 trial reported a 15.2% visceral-fat reduction against a 5.0% gain on placebo, and the pooled analysis of both phase 3 trials a treatment effect of −15.4% with subcutaneous fat preserved.[8][9] The effect lasted only while the drug was given: visceral fat reaccumulated after patients stopped.[10][11] The liver-fat trial and a 2026 meta-analysis of five randomised trials point the same way, again in people with HIV.[12][13] Outside HIV the record is small: a 12-week type 2 diabetes safety study, a 2012 trial in older adults with mild cognitive impairment, and a 2026 22-person placebo-controlled pilot of low-dose tesamorelin over 10 weeks that found no significant change in cognition, body composition or glucose tolerance.[14][15][20] A small Phase 2 trial in peripheral nerve injury (NCT03150511, open since 2018) is listed as recruiting.[21] In people with HIV, a 2025 trial found no cognitive benefit.[16] ClinicalTrials.gov lists 23 registered tesamorelin studies, excluding one record labelled a mock study (queried October 12, 2026).[17]

What the Egrifta Label Says About Safety

These are the published facts for the approved human medicine. They describe Egrifta in its labelled population, not research material.[1]

When Egrifta's EU application was withdrawn in 2012, the EMA committee's provisional view was that it could not be approved, citing raised IGF-1 as a major safety concern, unclear clinical benefit of the fat reduction, and no long-term safety data.[3]

Regulatory Status in 2026

Where tesamorelin stands as of October 7, 2026.
  • United States. FDA-approved prescription medicine (Egrifta, Egrifta SV, Egrifta WR) for one indication: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Not approved for weight loss or any other use.[2]
  • European Union. No marketing authorisation. The only centralised application was withdrawn on June 21, 2012, during review.[3]
  • Canada. Approved in 2014; both Egrifta product listings are now marked cancelled.[4]
  • United Arab Emirates. We found no UAE registration for Egrifta or tesamorelin in public registries. Public registry coverage is limited, so this is not proof of absence and not a legal opinion; see the Dubai legality brief.
  • Sport. Tesamorelin is named among the GHRH analogues in WADA section S2.2.4 and is prohibited at all times, in and out of competition, on both the 2026 and 2027 Lists.[18][19]

Tesamorelin at Remy Research: Dubai Listing Facts

The product pages are the source of truth for price and stock. The table records the catalogue as of October 12, 2026.

Product Format and AED tiers Documentation
10mg vial Lyophilised powder, sealed glass vial · AED 355 · 2+ AED 330 · 5+ AED 300 · in stock ≥99% HPLC line standard; METS Lab batch report TSM10V-001 (99.31% HPLC)
20mg pen Pre-filled pen · AED 700 · currently out of stock ≥99% HPLC line standard
Genovare 25mg pen Aqueous pre-filled pen · AED 1,000 · in stock 99%+ line standard

Remy Research publishes batch-specific Janoshik reports in the lab results library, which lists every published batch. The only published tesamorelin batch report is METS Lab’s report for the 10mg vial (TSM10V-001); this page does not imply one exists for any other format or lot. Delivery terms across the emirates are on the delivery page.

Checking a Tesamorelin Supplier in the UAE

UAE listings for research tesamorelin range widely in price and format, and most quote "99% purity" without a report you can trace to a batch. Before ordering from any supplier, including this one, check:

What This Page Does Not Claim

Our Research Standards

This guide relies on the current FDA label, regulator records and primary trial literature, each checked on October 6–7, 2026. Listing facts come from the Remy Research catalogue on the same date. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

Tesamorelin Dubai FAQ

Where can I buy tesamorelin in Dubai?

Two products share the name. Egrifta, the approved medicine, is a US prescription drug, and we found no UAE registration for it. Research-use-only tesamorelin is sold by UAE peptide suppliers; Remy Research lists a 10mg vial and a Genovare 25mg pen for in-vitro laboratory research only, not for human or veterinary use. Whatever the source, ask for a batch-linked certificate with identity confirmation before ordering.[1]

Is tesamorelin FDA-approved?

Yes, as Egrifta (2010), Egrifta SV (2018) and Egrifta WR (2025), for one indication: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for weight loss; the label calls its effect weight neutral. Research-use tesamorelin is not an approved product.[2][1]

Is Egrifta available in the UAE?

We found no UAE registration for Egrifta or tesamorelin in public registries as of October 7, 2026, although registry coverage is limited. Egrifta was never authorised in the EU, where the application was withdrawn in 2012, and its Canadian listings are now cancelled.[3][4]

How much does tesamorelin cost in the UAE?

As of October 12, 2026, Remy Research lists the Tesamorelin 10mg vial at AED 355, AED 330 each for 2+ and AED 300 each for 5+, and the Genovare 25mg pen at AED 1,000; the 20mg pen is out of stock. Price says nothing about purity or identity; the batch certificate does.

Is Remy Research tesamorelin third-party tested?

The ProPeptide vial and pen are supplied to a ≥99% HPLC line standard. The 10mg vial also has a published METS Lab batch report (TSM10V-001: 99.31% HPLC purity, 9.98 mg content). The Genovare pen is supplied to the 99%+ line standard. Every published batch report is listed in the lab results library.

Is tesamorelin banned in sport?

Yes. WADA names tesamorelin among the GHRH analogues in section S2.2.4, prohibited at all times, in and out of competition, on the 2026 and 2027 Prohibited Lists.[19]

What safety issues does the Egrifta label list?

For the approved medicine in its labelled population: raised IGF-1, glucose intolerance, fluid retention, hypersensitivity and injection-site reactions, and antibodies in about half of patients. It is contraindicated in pregnancy, active malignancy and pituitary disruption. These label facts describe Egrifta, not research material.[1]

Does the effect of tesamorelin last after stopping?

Not in the trials. In the phase 3 extension studies, visceral fat reaccumulated after patients stopped treatment.[10][11]

Sources

  1. U.S. Food and Drug Administration / DailyMed. EGRIFTA SV (tesamorelin for injection) prescribing information, Theratechnologies Inc., label effective July 29, 2026 (indication, warnings, adverse reactions, immunogenicity, description). dailymed.nlm.nih.gov ↩
  2. U.S. Food and Drug Administration. Drugs@FDA: application 022505 (EGRIFTA, Theratechnologies), original approval November 10, 2010; supplemental approval March 25, 2025. accessdata.fda.gov ↩
  3. European Medicines Agency. Egrifta (tesamorelin), EMEA/H/C/002427: application withdrawn by Ferrer Internacional S.A. on June 21, 2012; questions and answers EMA/CHMP/475021/2012. ema.europa.eu ↩
  4. Health Canada Drug Product Database. EGRIFTA (tesamorelin acetate), DINs 02423677 and 02438712, both listed as cancelled (checked October 6, 2026). health-products.canada.ca ↩
  5. Theratechnologies Inc. Annual information exhibit filed with the U.S. SEC (2020): FDA approval of the F4 formulation (EGRIFTA SV) announced November 5, 2018. sec.gov ↩
  6. Theratechnologies Inc. press release (March 25, 2025), reposted by EATG: FDA approves EGRIFTA WR (tesamorelin F8) supplemental BLA. eatg.org ↩
  7. National Center for Biotechnology Information. PubChem Compound Summary for CID 16137828, Tesamorelin (C221H366N72O67S; CAS 218949-48-5). pubchem.ncbi.nlm.nih.gov/compound/16137828 ↩
  8. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi: 10.1056/NEJMoa072375 · PMID: 18057338 ↩
  9. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi: 10.1210/jc.2010-0490 · PMID: 20554713 ↩
  10. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. doi: 10.1097/QAD.0b013e32830a5058 · PMID: 18690162 ↩
  11. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. doi: 10.1097/QAI.0b013e3181cbdaff · PMID: 20101189 ↩
  12. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. doi: 10.1016/S2352-3018(19)30338-8 · PMID: 31611038 ↩
  13. Badran AS, Helal A, Shata KS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. doi: 10.1016/j.orcp.2026.01.002 · PMID: 41545261 ↩
  14. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. doi: 10.1371/journal.pone.0179538 · PMID: 28617838 ↩
  15. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. doi: 10.1001/archneurol.2012.1970 · PMID: 22869065 ↩
  16. Ellis RJ, Vaida F, Hu K, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. doi: 10.1093/infdis/jiaf012 · PMID: 39813152 ↩
  17. ClinicalTrials.gov. Studies with tesamorelin as intervention: 24 records, 23 excluding one record labelled a mock study (queried October 12, 2026). clinicaltrials.gov ↩
  18. World Anti-Doping Agency. 2026 Prohibited List (in force January 1, 2026), S2 peptide hormones: GHRH and its analogues, e.g. tesamorelin. wada-ama.org ↩
  19. World Anti-Doping Agency. 2027 Prohibited List (in force January 1, 2027), section S2.2.4 Growth hormone releasing factors: GHRH and its analogues, e.g. tesamorelin; prohibited at all times. wada-ama.org ↩
  20. Stewart CE, French KP, Wright TJ, et al. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci. 2026;44:100616. doi: 10.1016/j.ensci.2026.100616 · PMID: 42382101 ↩
  21. ClinicalTrials.gov. Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury, NCT03150511. Johns Hopkins University; Phase 2; recruiting since 2018 (checked October 12, 2026). clinicaltrials.gov ↩

For current stock and price, use the Tesamorelin 10mg vial page. For the full evidence review, see the Tesamorelin research review; for wider sourcing checks, the Dubai research-vial map.